Related Experiment Video

Updated: Jul 19, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Pralatrexate: an emerging new agent with activity in T-cell lymphomas

Owen A O'Connor1

  • 1Laboratory of Experimental Therapeutics for Lymphoproliferative Malignancies, Department of Medicine, Division of Hematologic Malignancies, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York 10021, USA. oconnoro@mskcc.org

Current Opinion in Oncology
|September 22, 2006
PubMed
Abstract

Insights

Pralatrexate, a novel antifolate, shows significant activity against T-cell lymphomas (TCL) by targeting the reduced folate carrier type 1 (RFC-1). Early studies indicate superior efficacy and manageable toxicity in these challenging hematologic malignancies.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • T-cell lymphomas (TCL) are aggressive hematologic malignancies with poor prognoses.
  • Novel therapeutic strategies are crucial for improving outcomes in TCL patients.

Purpose of the Study:

  • To review emerging information on pralatrexate, a novel antifolate, for treating T-cell lymphomas.
  • To highlight pralatrexate's mechanism of action and clinical activity in TCL.

Main Methods:

  • Review of preclinical and clinical studies on pralatrexate.
  • Evaluation of pralatrexate's affinity for reduced folate carrier type 1 (RFC-1).
  • Analysis of early phase (I and II) clinical trial data in TCL.

Main Results:

  • Pralatrexate exhibits high affinity for RFC-1, enhancing cellular internalization.
  • Preclinical studies show pralatrexate is superior to traditional antifolates in TCL models.
  • Early clinical studies demonstrate marked activity across various TCL subtypes, with stomatitis as dose-limiting toxicity.

Conclusions:

  • Pralatrexate is a novel antifolate with enhanced cellular uptake and significant activity in T-cell lymphomas.
  • Pralatrexate demonstrates superiority over methotrexate in preclinical settings.
  • Ongoing research focuses on pharmacokinetics and expanding its use in TCL and B-cell lymphomas.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...